179 filings
8-K
OCUP
Ocuphire Pharma Inc
17 Apr 24
Departure of Directors or Certain Officers
4:23pm
8-K
OCUP
Ocuphire Pharma Inc
27 Mar 24
Regulation FD Disclosure
4:26pm
8-K
OCUP
Ocuphire Pharma Inc
8 Mar 24
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
8:21am
8-K
OCUP
Ocuphire Pharma Inc
16 Feb 24
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
4:03pm
8-K
OCUP
Ocuphire Pharma Inc
5 Dec 23
Departure of Directors or Certain Officers
7:15pm
8-K
er77qv5ov iyhckq
27 Nov 23
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
8:45am
8-K
mb2jhy6 0awp5
13 Nov 23
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
8:12am
8-K
eafuh5y5ezv9c
2 Nov 23
Ocuphire Corporate Presentation November 2023
8:44am
8-K
hclki5w0y bkr7jskwz8
1 Nov 23
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
4:21pm
8-K
0uu9k9eie6a1swrqku
27 Sep 23
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024
8:45am
8-K
ibsym2gaz56lozsmu jk
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
hu1 doew9yk12l0wrb
1 Aug 23
Restore Vision & Clarity Ocuphire Corporate Presentation August 2023
11:21am
8-K
n17uzt 2g2hyq1lr7
14 Jun 23
Departure of Directors or Certain Officers
4:31pm
8-K
3bym4ha 8kbbf25fh4
8 Jun 23
Submission of Matters to a Vote of Security Holders
5:58pm
8-K
jj93ptllwx
2 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:30pm
8-K
x5i8xnuc
15 May 23
Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update
8:07am
8-K
rexar7 n0k
21 Apr 23
Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer
8:10am
8-K
nkc xp20tvzte
30 Mar 23
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update
9:05am
8-K
z807a8b r8r
25 Jan 23
Regulation FD Disclosure
4:15pm
8-K
e6fcmfxxd ihii8
6 Dec 22
Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol® Eye Drops for Reversal of Mydriasis
6:37am